Protecting Access to Medication Abortion Act of 2023

S 237, the Protecting Access to Medication Abortion Act of 2023, modifies federal safety requirements for mifepristone (used in medication abortions) to expand access. The bill requires the FDA to remove in-person dispensing rules, allow telehealth prescriptions, and permit certified pharmacies to mail the drug directly to patients. It directly affects patients seeking medication abortion and healthcare providers/pharmacies dispensing mifepristone. The law mandates these changes for mifepristone’s risk evaluation and mitigation strategy (REMS), while preserving FDA authority to adjust safety measures based on scientific evidence.